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In the oxyntic mucosa of the mammalian stomach, histamine is stored in ECL
cells and in mucosal mast cells. In the rat, at least 80 percent of oxyntic mucosal
histamine resides in the ECL cells. Histamine is a key factor in the regulation of
gastric acid secretion. Following depletion of ECL-cell histamine by treatment
with ax-fluoromethylhistidine (a-FMH), basal acid secretion was reduced, and
gastrin-stimulated acid secretion was abolished. Vagally-induced acid secretion
(by insulin injection or pylorus ligation) was unaffected by a-FMH treatment
but inhibited by an H2 antagonist. These results suggest that gastrin stimulates
acid secretion via release ofECL-cell histamine, whereas vagally-induced acid
secretion-although histamine-dependent-does not rely on ECL-cell histamine.
Gastrin is known to have a trophic effect on the oxyntic mucosa. By combining
long-term hypergastrinemia with continuous infusion of a-FMH, we were able
to show that gastrin-evoked trophic effects in the stomach do not depend on
ECL-cell histamine.
INTRODUCTION
In the oxyntic mucosa, between one and two percent ofthe cells are endocrine [1-4].
In the rat, approximately 65 percent of the endocrine cells are ECL cells, 10 percent are
somatostatin (D) cells, 25 percent areA-like cells and a few are D1/Pcells [3, 5]. They are
all "closed" inthatthey do nothave direct contact withthegland lumen. Thepeptide hormone
of the ECL cell has not yet been identified. However, it has been suggested that they
secrete a calciotropic/osteotrophic hormone [6, 7].
Besides the peptide hormone, the ECLcells are known to produce and store histamine
[8, 9]. The oxyntic mucosa is rich in histamine, but the cellular storage sites differ from
one species to another [5]. In some species, the main storage site is mast cells (for example
dog and man), whereas in other species the main storage site is ECLcells (rat and mouse).
The ECL cells are under both functional and trophic control ofgastrin, and their possible
role, andthat ofhistamine, in the functional control ofthe parietal cells has attracted much
attention [10]. The acute response to gastrin involves release of histamine and activation
ofhistidine decarboxylase (HDC)d [11-13]. Long-term stimulation with gastrin is known
to cause growth ofthe oxyntic mucosa and hyperplasia ofthe ECL cells [14-17]. We will
here discuss current knowledge ofthe physiological role ofECL-cell histamine.
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INHIBITION OF HISTAMINE SYNTHESIS
Histamine is produced by the decarboxylation of L-histidine. This amino acid is the
only one containing an imidazole ring. Animals do not synthesize this ring structure, which
must be supplied from other organisms, i.e., bacteria and plants [18]. Decarboxylation of
histidine is thought to be the chief source ofhistamine in all mammals [19]. The enzyme
HDC catalyzes this reaction. The non-specific aromatic amino acid decarboxylase is also
capable ofdecarboxylating histidine; however, HDC is quantitatively much more important
[20, 21]. HDC is present in the oxyntic mucosa and has been localized to the ECLcells of
the rat stomach [22]. The HDC activity ofthe oxyntic mucosa is high in species where the
ECL cells constitute the predominant histamine-containing cell population. On the other
hand, in species in which the oxyntic mucosa contains large numbers of mast cells and
few ECLcells, the HDC activity has either been hard to detect or can be measured at very
low levels only [23-25]. Interestingly, an inverse relationship between the histamine-
forming capacity of the gastric mucosa and the sensitivity ofparietal cells to exogenous
histamine has been found when comparing different species [21].
One way of studying the role of ECL-cell histamine would be to inhibit the hista-
mine-forming enzyme HDC and, thereby, deplete histamine from the tissue. This can be
accomplished with a-fluoromethylhistidine (ax-FMH), which is an inhibitor of this
enzyme. a-FMH is a so-called suicide substrate, and its mechanism of action has been
studied in detail [26-29]. The inhibition ofa-FMH is irreversible in the sense that dialysis
of the enzyme ax-FMH complex does not restore enzyme activity. Available data indicate
that a-FMH is an enzyme-activated and highly specific inhibitor [30]. In vivo, a-FMH has
been found to be a specific inhibitor ofHDC, but total inhibition ofHDC activity has been
difficult to achieve [28, 31, 32]. In most tissues, except brain and stomach, the histamine
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Figure 1. Rats treated with a-FMH (30 mg/kg,hr) by i.v. (2,6,8 hr) or s.c. (12,18,24 hr) infu-
sion for up to 24 hr. Histamine concentrations were determined in oxyntic mucosal homogenate.
Mean + SEM, n = 4-6.
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content didnotdecrease appreciably afterasingle injection ofa-FMH [28, 32]. In ourearly
work with a-FMH, we treated rats orally twice daily for up to eight days and observed a
reduction of the concentration of oxyntic mucosal histamine by 70 to 75 percent [33].
However, with twice daily dosing, the activity ofHDC was not maximally inhibited over
the 24-hour period. Instead, we started to use continuous infusion ofa-FMH via osmotic
minipumps to obtain aconstant level ofinhibition. Figure 1 shows how fast histamine dis-
appeared from the oxyntic mucosa over a time span of 24 hours. After 12 hours infusion
ofthe inhibitor maximal decrease was reached (80 to 85 percent). Despite prolonged infu-
sion for up to six weeks, there was no further decrease in oxyntic histamine.
Immunocytochemistry using histamine antibody revealed a virtual lack of histamine
immunostaining in the ECL cells following a-FMH. On the other hand, histamine in the
mast cells appeared unaffected [34]. From these data, we conclude thatECL-cell histamine
represents at least 80 percent of the total histamine in rat oxyntic mucosa.
ECL-CELL HISTAMINE AND GASTRIC ACID SECRETION
The finding that H2-receptor antagonists inhibit not only histamine-stimulated but
also gastrin- and vagus-stimulated acid secretion suggests that endogenous histamine
plays a central role in the gastric acid secretory response [35, 36]. There are two prevailing
hypotheses that attempt to define how histamine regulates the activity ofthe parietal cells
(for recent reviews, see [10, 35-39]). In brief, the transmission hypothesis argues that his-
tamine is the final mediator of acid secretion and that both gastrin and vagal excitation
stimulate the release ofhistamine, leading to acid secretion. In a series ofstudies, Waldum
et al. [40] have shown that gastrin is capable ofreleasing histamine from the isolated, per-
fused rat stomach in quantities that are sufficient to stimulate the parietal cells. The alter-
native hypothesis (i.e., the permission hypothesis) maintains that histamine acts as an
amplifier of the direct actions of gastrin and acetylcholine on the parietal cells [41, 42].
Regardless of the model, it is important to identify the physiologically relevant local
source of histamine. In rodents, most of the histamine is associated with the ECL cells,
which readily release histamine in response to gastrin. In most ofthe larger mammals, the
oxyntic mucosal histamine resides mainly in mast cells [5]. However, the gastric mast
cells do not respond to gastrin [43]. Thus, although in the larger mammals the ECL cells
contain a minor portion ofthe total gastric histamine, they may still represent the physio-
logically relevant source of histamine for acid secretion, provided that they respond to
stimuli in the same manner as the ECL cells in the rat stomach [44, 45].
To study the role ofECL-cell histamine in the regulation ofgastric acid secretion, we
treated chronic gastric fistula rats with cx-FMH by continuous subcutaneous infusion via
osmotic minipump for two to six days [46], which resulted in an 85 percent reduction of
the oxyntic mucosal histamine concentration. Acid-output was measured in these rats
before and after stimulation with histamine, gastrin and insulin. We have no evidence that
a-FMH directly impaired parietal cell activity [46].
Basal acid secretion was reduced by approximately 60 percent in aX-FMH-treated rats
compared to vehicle-treated rats, suggesting an involvement of ECL-cell histamine in
basal acid secretion. However the H2 antagonist ranitidine inhibited basal acid secretion
by about 85 percent. The residual acid secretion after ax-FMH treatment could reflect
either an incomplete depletion of ECL-cell histamine or the contribution of histamine
from another source than ECL cells. Pirenzepine, an Ml antagonist, inhibited basal acid
secretion by about 85 percent, indicating that an intact cholinergic pathway is necessary
for a full basal acid response.
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Histamine stimulated acid secretion in the gastric fistula rat. The response to hista-
mine was not affected by pretreatment with x-FMH but prevented by ranitidine (Figure
2). The latter effect was independent of the mucosal histamine concentration. Gastrin
stimulated acid secretion to a somewhat higher level than that reached after histamine
stimulation. Pretreatment with either a-FMH or ranitidine prevented the stimulatory effect
of gastrin (Figure 3). However, insulin stimulated acid secretion to the same level in both
vehicle- and a-FMH-treated rats (Figure 4). Both ranitidine andpirenzepine prevented the
response to insulin. In addition, we observed that ranitidine and pirenzepine, but not a-
FMH, inhibited the acid secretion induced by pylorus ligation, which causes vagal stimu-
lation [46, 47].
Depletion of ECL-cell histamine resulted in a near total loss of the acid response to
gastrin. The minute response that remained could be due to the release of the small
amounts ofhistamine that remained in the ECL cells. Alternatively, some other histamine
source might be responsible. Whatever the explanation, it is clear that gastrin depends on
ECL-cell histamine to exert its effect on the parietal cells. These data are in agreement
with other studies in rat anddog, showing that infusion ofgastrin produces adose-dependent
increase in histamine release [44, 48]. The response to vagal stimulation was not affected
by depletion ofECL-cell histamine, an observation that is supported by a recent study in
dogs in which pentagastrin infusion stimulated histamine release as well as acid secretion,
whereas methacholine infusion stimulated acid output only [49]. In isolated parietal cells
from several different species, cholinergic agents clearly stimulate aminopyrine accumu-
lation whereas gastrin has a weak effect only, favoring the view thathistamine plays arole
in producing the full acid secretory response to gastrin [41, 50-54].
The M1 antagonist pirenzepine was able to inhibit acid secretion stimulated by both
insulin andpylorus ligation despite thefactthatthe muscarinic receptor on theparietal cell
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Figure 2. Histamine-stimulated gastric acid secretion in chronic rfstula rats pretreated with
vehicle (left) or a-FMH 3 mg/kg,hr (right) for at least two days. Histamine was given during the
experiment (55 mollkg,h given s.c.). Ranitidine was given 2 hr before the experiment (800 mol/lkg
given p.o.) and during the experiment (50 mollkg,hr given s.c.). Mean + SEM, n = 10-12.
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Figure 3. Gastrin-17-stimulated gastric acid secretion in chronic fistula rats pretreated with
vehicle (left) or a-FMH 3 mg/kg,h (right) for at least two days. Gastrin-17 was given during the
experiment (5 nmol/kg,hr given s.c.) Ranitidine was given 2 hr before the experiment (800 mol/kg
given p.o.) and during the experiment (50 mol/kg,hr given s.c.). Mean + SEM, n = 8-12.
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Figure 4. Insulin-stimulated gastric acid secretion in chronic fistula rats pretreated with vehicle
(left) or a-FMH 3 mg/kg,h (right) for at least two days. Insulin was given as a bolus injection
(0.6 IU/kg given s.c.). Ranitidine was given 2 hr. before the experiment (800 mol/kg given p.o.) and
during the experiment (50 mollkg,hr given s.c.). Pirenzepine was given during the experiment (1
mg/kg,h given s.c.) Mean + SEM, n = 8-18.
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is ofthe M3 subtype [55]. This finding is in line with previous observations indicating that
M1 receptors, probably associated with neurons in intramural ganglia, are physiologically
important in the regulation of acid secretion [56, 57]. The inhibitory effect of ranitidine
on gastrin- or vagally-stimulated acid secretion in a-FMH-treated rats could reflect small
amounts ofhistamine remaining in the ECL cells or it could reflect the contribution ofhis-
tamine from another source (mast cells?).
Gastrin is able to stimulate aminopyrine accumulation in parietal cells isolated from
pig and dog, but not from rat [41, 58]. This seems to correlate with the basal level of
cAMPin the parietal cells ofthese different species, which is low in the rat compared with
pig and dog [58-61]. In isolated pig parietal cells, pentagastrin induces a dose-dependent
increase in aminopyrine accumulation, which could not be inhibited by an H2 antagonist
[62]. The effect of pentagastrin was reduced by inhibition of protein kinase A, showing a
dependence of the cAMP level for the response to pentagastrin. Gastrin induces an
increase in the intracellular Ca2+ levels in both ECL cells and parietal cells from rats but
the effect on the parietal cell was blocked by an H2 antagonist [63]. However, by adding
DBcAMP in addition to the H2 antagonist the response of the parietal cells to gastrin was
restored. These results suggest that the gastrin response of the parietal cell depends upon
the level of cAMP and that an elevation of intracellular cAMP plays a permissive role in
the action of gastrin on the parietal cell [62, 63]. It has also been shown that carbachol is
dependent on the cAMP level to be effective in stimulating aminopyrine accumulation,
but the level of cAMP required may be lower for carbachol than for gastrin [58].
Ifwe try to translate these in vitro data to the in vivo situation in our experiments, the
depletion of ECL cell histamine would result in a lowering of the amount of local hista-
mine available to stimulate the parietal cells. This could result in a decrease in the cAMP
level in the parietal cells. Nonetheless, the cAMP level would still be enough for vagal
stimulation to elicit the same response as in control rats. Adding an H2 antagonist would
prevent the remaining histamine from binding to its receptor on the parietal cell and
would, thereby, lower the cAMP concentration to a level where vagal stimulation no
longer could induce acid secretion. In the rat, ECL cell histamine would then be crucial
for gastrin to exercise its acid-stimulating effect. Vagal stimulation might require smaller
amounts ofhistamine to attain a cAMPconcentration high enough to generate acid secre-
tion.Alternatively, vagal stimulation is capable ofreleasing histamine from mucosal mast
cells, resulting in acid production. It may be noted that mast cells are frequently found to
be associated with nerve terminals also in the digestive tract and that acetylcholine caus-
es release of histamine from mast cells [64].
ECL-CELL HISTAMINE AND ECL-CELL PROLIFERATION
Besides its action as a stimulant of gastric acid secretion, gastrin has a trophic effect
on the oxyntic mucosa [14-17]. The clinical significance ofthe trophic action ofgastrin has
been obvious for many years, for example, the gastric mucosal hyperplasia coincident with
Zollinger-Ellison syndrome and the mucosal atrophy observed following removal of the
gastric antrum [65, 66]. There has been some controversy over the years regarding the
question of whether gastrin has a trophic effect on tissues other than the oxyntic mucosa,
i.e., the small and large intestine and the pancreas. By using repeated injections of penta-
gastrin Johnson and co-workers have shown trophic effects on the intestines and in the pan-
creas [67, 68]. However experiments using exogenous gastrin-17 or manipulation of the
circulating endogenous gastrin levels have not confirmed these results [69-71]. Gastrin
releases ECL-cell histamine, and it has been suggested that the released histamine mediates
the trophic effect ofgastrin [72, 73]. Histamine has been found to influence the mitotic rate
188Andersson et al: ECL-cell histamine
Number of ECL cells per visual field
600
500
400
300
200
Vehicle a-FMH Omeprazole a-FMH +
Omeprazole
Figure 5. ECL-cell density aftersix weeks administration ofvehicle, a-FMH (3 mg/kg,hrgiven
s.c.), omeprazole (400 mol/kg given p.o.) orthe combination ofa-FMH + omeprazole. The cells
were visualized by immunofluorescence using antibodies against HDC. Mean + SEM, n = 7-9.
of cells in the stomach and intestine of experimental animals [74, 75]. Recently it was
argued that terfenadine, an Hi-antagonist, inhibited ECL-cell proliferation induced by
hypergastrinemia [76]. There are also reports favoring the existence of an H3 receptor on
the ECL cell modulating the gastrin-stimulated histamine secretion [77]. In other studies,
exogenous histamine has not been found to mimic the trophic action ofgastrin [78, 79]. We
examined the possible involvement ofECL-cell histamine in the trophic response to long-
term hypergastrinemia inrats [80]. Rats weretreated with ahigh doseofomeprazole and/or
a-FMH for six weeks. We found that treatment with a-FMH induced an increase in the
plasmagastrin level, which was stable during the treatmentperiod. Both the histamine con-
centration and the HDC activity in the oxyntic mucosa were reduced by approximately 80
percent compared to control rats. a-FMH alone increased the ECL cell number approxi-
mately two-fold. Omeprazole treatment resulted in sustained hypergastrinemia regardless
of whether or not they received a-FMH. The hypergastrinemia resulted in an increase in
stomach and mucosal weight as well as in mucosal thickness. Omeprazole alone raised the
oxyntic mucosal histamine concentration and HDC activity while a combination of
omeprazole and a-FMH reduced the histamine concentration and HDC activity to the same
level as x-FMH only. The numberofECLcells was much increased in both groups and the
ECL cells were found notably higher up in the glands, although they still predominated in
the basal part (Figure 5). There were no statistically significant differences between rats
treated with omeprazole or omeprazole plus a-FMH. We conclude, therefore, that the
trophic response to gastrin occurs independently ofECL-cell histamine.
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CONCLUSIONS
Gastrin stimulates acid secretion via the release of ECL-cell histamine. Although
vagally induced acid secretion does not depend on ECL-cell histamine, it depends on a
histaminergic pathway. Gastrin-evoked trophic effects in the oxyntic mucosa (including
ECL cell hypertrophy/hyperplasia) occurs independently ofECL-cell histamine.
REFERENCES
1 Ito, S. Functional gastric morphology. In: Johnson, L.R., ed. Physiology of the gastrointestinal
tract. New York: Raven Press; 1987, pp. 817-851.
2. Helander, H.F. The cells ofthe gastric mucosa. Int. Rev. Cytol. 70:217-89, 1981.
3. Hakanson, R., Bottcher, G., Sundler, F., and Vallgren, S. Activation and hyperplasia of gastrin
and enterochromaffin-like cells in the stomach. Digestion 35(suppl 1):23-41, 1986.
4. Simonsson, M., Eriksson, S., Hakanson, R., Lind, T., Lonroth, H., Lundell, L.,O'Conner, D.T.,
and Sundler, F. Endocrine cells in the human oxyntic mucosa. Ahistochemical study. Scand. J.
Gastroenterol. 23:1089-1099, 1988.
5. HAkanson, R., Bottcher, G., Ekblad, E., Panula, P., Simonsson, M., Dohlsten, M., Hallberg, T.,
and Sundler, F. Histamine in endocrine cells in the stomach. A survey ofseveral species using a
panel ofhistamine antibodies. Histochemistry 86:5-17, 1986.
6. Persson, P., Hakanson, R., Axelson, J., and Sundler, F Gastrin releases a blood calcium- lower-
ing peptide from the acid-producing part of the rat stomach. Proc. Natl. Acad. Sci. USA
86:2834-2838, 1989.
7. Persson, P. and HAkanson, R. The gastrin-gastrocalcin hypothesis. In: Hakanson, R., Sundler, F,
ed. The stomach as an endocrine organ. Fernstrom Symposium, No. 15. Amsterdam: Elsevier;
1991, pp. 449-460.
8. HAkanson, R., Owman, C., Sporrong, B., and Sundler, F Electron microscopic identification of
the histamine-storing argyrophil, enterochromaffin-like cells in the rat stomach. Z. Zellforsch.
122:460-466, 1971.
9. Rubin, W. and Schwartz, B. Electron microscopic radioautographic identification of the ECL
cell as the histamine-synthesizing endocrine cell in the rat stomach. Gastroenterology 77:458-
467, 1979.
10. Hakanson, R. and Sundler, F. Do histamine-storing cells in the gastric mucosa mediate the acid-
stimulating action of gastrin. In: Uvnas, B., ed. Handbook of experimental pharmacology. Vol.
97. Histamine and histamine antagonists. Berlin: Springer; 1991, pp. 325-346.
11. Hakanson, R., Kroesen, J.H., Liedberg, G., Oscarson, J., Rehfeld, J.F., and Stadil, F Correlation
between serum gastrin concentration and rat stomach histidine decarboxylase activity. J.
Physiol. 243:483-498, 1974.
12. Ryberg, B., Mattsson, H., Larsson, H., and Carlsson, E. Correlation between inhibition of gas-
tric acid secretion, plasma gastrin, and oxyntic mucosal histidine decarboxylase activity in the
rat. Scand. J. Gastroenterol. 24:287-292, 1989.
13. Chen, D., Monstein, H.J., Nylander, A.G., Zhao, C.M., Sundler, F, and Hakanson, R. Acute
responses ofrat stomach enterochromaffinlike cells to gastrin: secretory activation and adapta-
tion. Gastroenterology 107:18-27, 1994.
14. Johnson, L. Regulation of gastrointestinal growth. In: Johnson, L., ed. Physiology of the gas-
trointestinal tract. New York: Raven; 1987. pp. 301-344.
15. Larsson, H., Carlsson, E., Mattsson, H., Lundell, L., Sundler, F., Sundell, G., Wallmark, B.,
Watanabe, T., and Ha.kanson, R. Plasma gastrin and gastric enterochromaffinlike cell activation
and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats.
Gastroenterology 90:391-399, 1986.
16. Ryberg, B., Axelson, J., Hfikanson, R., Sundler, F, and Mattsson, H. Trophic effects of contin-
uous infusion of [Leul5]-gastrin-17 in the rat. Gastroenterology 98:33-38, 1990.
17. Hakanson, R., Tielemans, Y., Chen, D., Andersson, K., Mattsson, H., and Sundler, F. Time-
dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats.
Gastroenterology 105:15-21, 1993.
18. Ames, B. The biosynthesis of histidine. In: McElroy, W. and Glass, H.B., eds. Symposium on
amino acid metabolism. Baltimore: J. Hopkins Press; 1955. pp. 357-372.
19. Ganrot, P., Rosengren, A.M., and Rosengren, E. On the presence of different histidine decar-
boxylation enzymes in mammalian tissues. Experentia 17:263-263, 1962.Andersson et al: ECL-cell histamine 191
20. Lovenberg, W., Weissbach, H., and Udenfriend, S. Aromatic L-amino acid decarboxylase. J.
Biol. Chem. 237:89-93, 1962.
21. Kahlson, G., Rosengren, E., and Svensson, S.-E. Histamine and gastric acid secretion with spe-
cial reference to the rat. In: Holton, P., ed. Pharmacology of gastrointestinal motility and secre-
tion, Volume 1. Oxford: Pergamon; 1973, pp. 41-102.
22. Kubota, H., Taguchi, Y., Tohyama, M., Matsuura, N., Shiosaka, S., Ishihara, T., Watanabe, T.,
Shiotani, Y., and Wada, H. Electron microscopic identification of histidine decarboxylase-con-
taining endocrine cells of the rat gastric mucosa. An immunohistochemical analysis.
Gastroenterology 87:496-502, 1984.
23. Aures, D., Davidson, W.D., and Hakanson, R. Histidine decarboxylase in gastric mucosa ofvar-
ious mammals. Eur. J. Pharmacol. 8:100-7, 1969.
24. Bergmark, J., Granerus, G., Henningsson, S., Lundell, L., and Rosengren, E. Histamine metab-
olism of the guinea-pig gastric mucosa. J. Physiol. 257:419-31, 1976.
25. Dencker, H., Kahlson, G., Kockum, I., Norryd, C., Rosengren, E. Histamine metabolism in
human gastric mucosa. Clin. Sci. Mol. Med. (suppl 42):225-31,1973.
26. Kollonitsch, J. Suicide substrate enzyme inactivators ofenzymes dependent on pyridoxal- phos-
phate: -fluoro amino acid and -fluoro amines. Design, synthesis and application: a contribution
to drug design. In: Filler, R. and Kobayashi, Y., eds. Biomedical aspects of fluorine chemistry.
New York: Elsevier; 1982. p 93.
27. Hayashi, H., Tanase, S., and Snell, E.E. Pyridoxal 5'-phosphate-dependent histidine decarboxy-
lase. Inactivation by alpha-fluoromethylhistidine and comparative sequences at the inhibitor-
and coenzyme-binding sites. J. Biol. Chem. 261:11003-11009, 1986.
28. Garbarg, M., Barbin, G., Rodergas, E., and Schwartz, J.C. Inhibition of histamine synthesis in
brain by alpha-fluoromethylhistidine, a new irreversible inhibitor: in vitro and in vivo studies. J.
Neurochem. 35:1045-1052, 1980.
29. Wada, H., Watanabe, T., Maeyama, K., Taguchi, K., and Hayashi, H. Mammalian histidine
decarboxylase and its suicide substrate, a-fluoromethylhistidine. In: Evangelopoulos A, ed.
Chemical and biological aspects ofvitamin B6 catalysis. New York: Liss; 1984, p. 245.
30. Watanabe, T., Taguchi, Y., Maeyama, K., and Wada, H. Formation ofhistamine: histidine decar-
boxylase. In: Uvniis, B., ed. Handbook of experimental pharmacology, Vol 97. Histamine and
histamine antagonists. Berlin: Springer; 1991, pp. 145-163.
31. Duggan, D.E., Hooke, K.F., and Maycock, A.L. Inhibition ofhistamine synthesis in vitro and in
vivo by S-alpha-fluoromethylhistidine. Biochem. Pharmacol. 33:4003-4009, 1984.
32. Maeyama, K., Watanabe, T., Taguchi, Y,, Yamatodani, A., and Wada, H. Effect of alpha- fluo-
romethylhistidine, a suicide inhibitor of histidine decarboxylase, on histamine levels in mouse
tissues. Biochem. Pharmacol. 31:2367-23670, 1982.
33. Andersson, K., Mattsson, H., and Larsson, H. The role of gastric mucosal histamine in acid
secretion and experimentally induced lesions in the rat. Digestion 46:1-9, 1990.
34. Andersson, K., Chen, D., Hakanson, R., Mattsson, H., and Sundler, F. Enterochromaffln-like
cells in the rat stomach: effect of alpha-fluoromethylhistidine-evoked histamine depletion. A
chemical, histochemical and electron-microscopic study. Cell Tissue Res. 270:7-13, 1992.
35. Black, J. Reflections on the analytical pharmacology of histamine h2-receptor antagonists.
Gastroenterology 105:963-968, 1993.
36. Black, J. and Shankley, N.P. How does gastrin act to stimulate oxyntic cell secretion? Trends
Pharmacol. Sci. 8:486-490, 1987.
37. Rangachari, P.K. Histamine: mercurial messenger in the gut [editorial]. Am. J. Physiol. 262:G1-
13, 1992.
38. Waldum, H.L., Sandvik, A.K., Brenna, E., and Petersen, H. Gastrin-histamine sequence in the
regulation ofgastric acid secretion. Gut 32:698-701, 1991.
39. Hersey, S.J. and Sachs, G. Gastric acid secretion. Physiol. Rev. 75:155-189, 1995.
40. Waldum, H.L. and Sandvik, A.K. Histamine and the stomach. Scand. J. Gastroenterol. 24:130-
139, 1989.
41. Soll, A.H. Secretagogue stimulation of [14C]aminopyrine accumulation by isolated canine pari-
etal cells. Am. J. Physiol. 238:G366-375, 1980.
42. Grossman, M.I. and Konturek, S.J. Inhibition ofacid secretion in dog by metiamide, ahistamine
antagonist acting on H2 receptors. Gastroenterology 66:517-21, 1974.
43. Soll, A.H., Toomey, M., Culp, D., Shanahan, F., and Beaven, M.A. Modulation of histamine
release from canine fundic mucosal mast cells. Am. J. Physiol. 254:G40-48, 1988.
44. Gerber, J.G. and Payne, N.A. The role of gastric secretagogues in regulating gastric histamine
release in vivo. Gastroenterology 102:403-408, 1992.192 Andersson et al: ECL-cell histamine
45. Redfem, J.S., Thirlby, R., Feldman, M., and Richardson, C.T. Effect of pentagastrin on gastric
mucosal histamine in dogs. Am. J. Physiol. 248:G369-375, 1985.
46. Andersson, K., Cabero, J.L., Mattsson, H., and Hakanson, R. Gastric acid secretion after deple-
tion of enterochromaffin-like cell histamine-a study with alpha-fluoromethylhistidine in rats.
Scand. J. Gastroenterol. 31:24-30, 1996.
47. Hakanson, R., Hedenbro, J., Liedberg, G., Sundler, F., and Vallgren, S. Mechanisms of gastric
acid secretion after pylorus and oesophagus ligation in the rat. J. Physiol. 305:139-149, 1980.
48. Sandvik, A.K., Waldum, H.L., Kleveland, P.M., and Schulze Sognen, B. Gastrin produces an
immediate and dose-dependent histamine release preceding acid secretion in the totally isolat-
ed, vascularly perfused rat stomach. Scand. J. Gastroenterol. 22:803-808, 1987.
49. Gerber, J. and Payne, N.A. The role of gastric histamine release in the acid secretory response
to pentagastrin and methacholine in the dog. Inflamm. Res. 44:327-334, 1995.
50. Berglindh, T. Potentiation by carbachol and aminophylline ofhistamine- anddb-cAMP- induced
parietal cell activity in isolated gastric glands. Acta Physiol. Scand. 99:75-84, 1977.
51. Cabero, J.L., Grapengiesser, E., Gylfe, E., Li, Z.Q., and Mardh, S. Effects ofgastrin on cytoso-
lic free Ca2+ in individual, acid-secreting rat parietal cells. Biochem. Biophys. Res. Comm.
183:1097-1102, 1992.
52. Cabero, J.L., Li, Z.Q., and Mardh, S. Gastrin potentiates histamine-stimulated aminopyrine
accumulation in isolated rat parietal cells. Am. J. Physiol. 261:G621-7, 1991.
53. Soll, A. and Berglindh, T. Physiology ofisolated gastric glands and parietal cells: receptors and
effectors regulating function. In: Johnson, L., ed. Physiology of the gastrointestinal tract. New
York: Raven Press; 1987. pp. 883-909.
54. Soll, A.H. The actions ofsecretagogues on oxygen uptake by isolated mammalian parietal cells.
J. Clin. Invest. 61:370-380, 1978.
55. Kajimura, M., Reuben, M.A., and Sachs, G. The muscarinic receptor gene expressed in rabbit
parietal cells is the M3 subtype. Gastroenterology 103:870-875, 1992.
56. Pagani, F., Schiavone, A., Monferini, E., Hammer, R., and Giachetti, A. Distinct muscarinic
receptor subtype (M, and M2) controlling acid secretion in rodents. Trends Pharmacol. Sci.
(suppl) 5:66-68, 1984.
57. Ekelund, M., HAkanson,R., and Vallgren, S. Effects of cimetidine, atropine and pirenzepine on
basal and stimulated gastric acid secretion in the rat. Eur. J. Pharmacol. 138:225-232, 1987.
58. Li, Z.Q., Cabero, J.L., and Mardh, S. Gastrin and carbachol require cAMP to elicit aminopyrine
accumulation in isolated pig and rat parietal cells. Am. J. Physiol. 268:G82-89, 1995.
59. Mardh, S., Song, Y.H., and Wallmark, B. Effects of some antisecretory drugs on acid produc-
tion, intracellular free Ca2+, and cyclic AMP production in isolated pig parietal cells. Scand. J.
Gastroenterol. 23:977-982, 1988.
60. Schepp, W. and Ruoff, H.J. Adenylate cyclase and H+ production ofisolated ratparietal cells in
response to glucagon and histamine. Eur. J. Pharmacol. 98:9-18, 1984.
61. Soll, A.H. and Wollin, A. Histamine and cyclic AMP in isolated canine parietal cells. Am. J.
Physiol. 237:E444-50, 1979.
62. Cabero, J.L., Li, Z.Q., and Mardh, S. Gastrin action on aminopyrine accumulation in isolated
pig parietal cells requires cAMP. Biochim. Biophys. Acta 1177:245-252, 1993.
63. Geibel, J., Abraham, R., Modlin, I., and Sachs, G. Gastrin-stimulated changes in Ca2+ concen-
tration in parietal cells depends on adenosine 3',5'-cyclic monophosphate levels.
Gastroenterology 109:1060-1067, 1995.
64. Fantozzi, R., Masini, E., Blandina, P., Mannaioni, P.F., and Bani-Sacchi, T. Release ofhistamine
from rat mast cells by acetylcholine. Nature 273:473-474, 1978.
65. Ellison, E. and Wilson, S.D. Further observations on factors influencing the symptomatology
manifest by patients with Zollinger-Ellison syndrome. In: Shuitka, T., Gilbert, L.A.L., and
Harrison, R.C., eds. Gastric secretion. New York: Pergamon; 1967. pp. 363-369.
66. Lees, F. and Grandjean, L.C. The gastric and jejunal mucosae in healthy patients with partial
gastrectomy. Arch. Intern. Med. 101:9437-9451, 1968.
67. Johnson, L.R. Gastrointestinal hormones and their functions. Ann. Rev. Physiol. 39:135- 158,
1977.
68. Johnson, L.R. Regulation ofgastrointestinal mucosal growth. World J. Surg. 3:477-86, 1979.
69. Hakanson, R., Blom, H., Carlsson, E., Larsson, H., Ryberg, B., and Sundler, F.
Hypergastrinaemia produces trophic effects in stomach but not in pancreas and intestines.
Regul. Pept. 13:225-233, 1986.
70. Oscarson, J., HAkanson, R., Liedberg, G., Lundqvist, G., Sundler, F., and Thorell, J. Variated
serum gastrin concentration: trophic effects on the gastrointestinal tract ofthe rat. Acta Physiol.
Scand. (suppl 475):2-27, 1979.Andersson et al: ECL-cell histamine 193
71. Chen, D., Nylander, A.G., Norlen, P., and Hakanson, R. Gastrin does not stimulate growth ofthe
rat pancreas. Scand. J. Gastroenterol. 31:404-410, 1996.
72. Modlin, I., Kim, H., Bilchik, A.J., Nilsson, O., Esterline, W.J., and Goldenring, J.R.
Pathobiology ofenterochromaffin-like cell tumor induction in mastomys. In: Hakanson, R. and
Sundler, F., eds. Fernstrom Foundation Series, Vol. 15. The Stomach as an endocrine organ.
Amsterdam: Elsevier; 1991, pp. 499-514.
73. Waldum, H.L., Brenna, E., Sandvik, A.K., and Petersen, H. Trophic effect of histamine on the
stomach. Scand. J. Gastroenterol. (suppl 180):137-142, 1991.
74. Pishva, N., Mann, M., Abtahi, ES., and Djahanguiri, B. Decreased mitotic activity in the stom-
ach, duodenum and colon of rats treated with high doses of histamine. Pharmacology 13:1-4,
1975.
75. Tutton, P.J. The influence of histamine on epithelial cell proliferation in thejejunum of the rat.
Clin. Exper. Pharmacol. Physiol. 3:369-373, 1976.
76. Modlin, I.M., Zhu, Z.H., Tang, L.H., Kidd, M., Lawton, G.P., Miu, K., et al. Evidence for a reg-
ulatory role for histamine in gastric enterochromaffln-like cell proliferation induced by hyper-
gastrinemia. Digestion 57:310-321, 1996.
77. Prinz, C., Kajimura, M., Scott, D.R., Mercier, F., Helander, H.F, and Sachs, G. Histamine secre-
tion from rat enterochromaffinlike cells. Gastroenterology 105:449-461, 1993.
78. Johnson, L.R., Aures, D., andYuen, L. Pentagastrin-induced stimulation of protein synthesis in
the gastrointestinal tract. Am. J. Physiol. 217:251-254, 1969.
79. Crean, G.P., Marshall, M.W., and Rumsey, R.D. Parietal cell hyperplasia induced by the admin-
istration ofpentagastrin (ICI 50,123) to rats. Gastroenterology 57:147-55, 1969.
80. Andersson, K., Hakanson, R., Mattsson, H., Ryberg, B., and Sundler, F Hyperplasia of hista-
mine-depleted enterochromaffinlike cells in rat stomach using omeprazole and alpha-fluo-
romethylhistidine. Gastroenterology 103:897-904, 1992.